Viread
NDC 69189-0401
Product Information
Viread is a NDA-approved product labeled by Avera Mckennan Hospital. Tenofovir is used with other HIV medications to help control HIV infection. It is supplied as a blue product. This product entry covers the primary NDC 69189-0401 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
GILEAD;4331;300
Code Structure Chart
Product Details
What is NDC 69189-0401?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TENOFOVIR DISOPROXIL FUMARATE (UNII: OTT9J7900I)
- TENOFOVIR ANHYDROUS (UNII: W4HFE001U5) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- STARCH, CORN (UNII: O8232NY3SJ)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
- ALUMINUM OXIDE (UNII: LMI26O6933)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- TRIACETIN (UNII: XHX3C3X673)
- HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 349251 - tenofovir disoproxil fumarate 300 MG Oral Tablet
- RxCUI: 349251 - tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet
- RxCUI: 352050 - Viread 300 MG Oral Tablet
- RxCUI: 352050 - tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread]
- RxCUI: 352050 - Viread 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet
* Please review the full disclaimer at the bottom of this page.